In the field of chemical factories and pharmaceuticals, glutathione raw material drugs are important raw materials for the production of liver-protecting and antioxidant preparations. The sulfhydryl group (-SH) in its molecular structure is prone to react with oxygen to form disulfides, resulting in reduced activity and increased impurities. 
The pre-treatment of the raw materials for chemical factories, glutathione raw material drug, requires the construction of a foundation for oxidation prevention. Whether it is the raw materials such as cysteine used in chemical synthesis or the bacteria and culture medium used in biological fermentation, they all need to be treated under inert gas (such as nitrogen) protection - the raw materials are stored using vacuum and light-proof packaging to avoid contact with air; during the fermentation inoculation process, the oxygen content in the fermentation tank is controlled, and inert gas is introduced to regulate the ventilation ratio to prevent the oxidation of glutathione precursor substances during fermentation, reducing the oxidation risk in subsequent processes and laying the foundation for the retention of chemical factories glutathione raw material drug activity.
The mild design of the synthesis process is the key to preventing oxidation of chemical factories ' glutathione raw material drugs. The current mainstream enzymatic synthesis process requires strict control of the reaction temperature (usually 18-25℃), avoiding the acceleration of sulfhydryl oxidation by high temperatures; a small amount of antioxidants (such as sodium bisulfite) is added to the reaction system to inhibit the oxidation reaction, and the pH value is controlled within the neutral range to reduce the impact of acid-base environment on the stability of sulfhydryl groups. The chemical synthesis method requires optimizing the reaction reagent ratio to avoid the use of strong oxidants and using a low-temperature reaction device (such as an ice-water bath) to ensure the structural stability of glutathione raw material drugs during synthesis, reducing the probability of oxidation impurity formation.
The environmental regulation in the storage and transportation is an extension of oxidation prevention for chemical factories, glutathione raw material drugs. Finished glutathione raw material drugs need to be packaged in double-layer light-proof aluminum-plastic bags， filled with inert gas to isolate oxygen， and the packaging is labeled with "low-temperature and light-proof" storage instructions； the storage temperature is strictly controlled at 2-8℃， with a relative humidity of ≤60%， to prevent the acceleration of oxidation due to temperature and humidity fluctuations. During transportation， a temperature-controlled box and oxygen concentration monitoring device are equipped to monitor the oxygen content inside the packaging in real time， preventing oxidation caused by packaging damage during transportation and ensuring that the glutathione raw material drugs remain qualified and active when they reach the drug manufacturing plant.
The comprehensive quality control monitoring throughout the process provides data support for oxidation prevention of chemical factories' glutathione raw material drugs. In each stage of synthesis， purification， storage， and storage， the content of oxidation impurities (such as glutathione disulfide) needs to be detected by high-performance liquid chromatography (HPLC)， and strict limit standards for impurities are set； stability tests simulate different temperature and humidity， oxygen concentration conditions， and regularly detect the activity changes of glutathione raw material drugs to provide a basis for optimizing oxidation prevention measures. This dynamic monitoring mechanism can promptly detect oxidation abnormalities， adjust process parameters or storage conditions to prevent the expansion of oxidation loss， and ensure the stable quality of each batch of glutathione raw material drugs.
Glutathione raw material drugs build a complete oxidation prevention system through the collaborative measures of raw material protection， process control， storage and transportation protection， and quality control monitoring. The effectiveness of oxidation prevention for glutathione raw material drugs is not only to meet the basic requirements of pharmaceutical preparation production， but also to ensure that the terminal products can exert their clinical value. With the development of pharmaceutical technology， the oxidation prevention technology for glutathione raw material drugs will be further upgraded， continuously optimizing in new antioxidant packaging， intelligent oxygen concentration monitoring， etc.， providing more stable raw material support for the pharmaceutical chemical factories.